Rituximab treatment of blistering disease
Not Applicable
- Conditions
- Pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid
- Registration Number
- JPRN-jRCTs031180220
- Lead Sponsor
- Kanaoka Miwa
- Brief Summary
Rituximab treatment of refractory pemphigus vulgaris resulted in a reduction in steroid dosage after 1 year and improvement in clinical symptoms and antibody titer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Patients who were diagnosed with pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid, with sufficient explanation and obtained research consent as sentences.
Exclusion Criteria
Patients diagnosed as inappropriate by the judgment of the doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method